Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
Alto Neuroscience (NYSE: ANRO) announced its participation in the Jefferies Global Healthcare Conference in New York from June 5-6, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
A live webcast of the fireside chat will be available on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available following the conclusion of the event.
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529163130/en/
Investor Contact:
Nick Smith
investors@altoneuroscience.com
Media Contact:
Jordann Merkert
media@altoneuroscience.com
Source: Alto Neuroscience, Inc.